Amoy Diagnostics is a company that develops molecular diagnostics for oncology precision medicine. The company was founded in 2008, in Xiamen, Fujian, China.
The company primarily looks to provide a portfolio of molecular diagnostics kits including but not limited to EGFR, RAS, ALK, BRAF, PIK3CA, and ROS1 testing kits, which are all CFDA and CE certified. The company serves over 300 hospitals in China as well as 50 other countries around the world.
With the outbreak of COVID-19, the company looks to provide quick and accurate diagnosis of diseases, especially the coronavirus. The company has developed a PCR-based test kits and has entered the NMPA (China's National Medical Products Administration) emergency approval channel.
The company's PCR-based test kits are meant to produce detection products for gene mutations, amplifications, nucleic acid extraction reagents, and other relation products. Their kits work with cancer, but they look to use them with the help of identifying coronavirus.
As Worries Grow Over Novel Coronavirus, Dx Industry Jumps Into Action
Coronavirus and the race to distribute reliable diagnostics
February 19, 2020
Documentaries, videos and podcasts
Xiamen, Fujian, China
PCR-based test kits